« Back
Home /
Abemaciclib

Abemaciclib

Item no.	HY-16297A-1mg
Manufacturer	MedChem Express
CASRN	1231929-97-7
Amount	1 mg
Quantity options	100 mg 10 mMx1 mL 10 mg 1 g 1 mg 200 mg 500 mg 50 mg 5 mg
Category	Oncology Neuroscience Neural Signaling Inhibitors & Compound Libraries Small Molecules By Organ Skin Cancer
Type	Inhibitors
Specific against	other
Purity	99.97
Citations	[1]Ku BM, et al. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma. Oncotarget.?2016 Mar 22;7(12):14803-13.\|[2]Yadav V, et al. The CDK4/6 inhibitor LY2835219 overcomes PLX4032 resistance resulting from MAPK reactivation and cyclin D1 upregulation. Mol Cancer Ther. 2014 Oct;13(10):2253-63.\|[3]Gelbert LM, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with NSC 613327. Invest New Drugs. 2014 Oct;32(5):825-37. ACS Appl Mater Interfaces. 2022 May 11;14(18):20628-20640.\|Adv Funct Mater. 2021 Apr 30.\|Adv Sci (Weinh). 2020 Aug 4;7(18):2000906.\|Adv Sci (Weinh). 2022 Aug 2;e2201834.\|Bioact Mater. 8 September 2021.\|Biochem Biophys Res Commun. 20 December 2021.\|Biomed Chromatogr. 2020 Jun;34(6):e4825.\|bioRxiv. 2023 Jan 25.\|bioRxiv. 2023 Jul 17.\|bioRxiv. 2023 Jul 19.\|bioRxiv. 2024 Dec 10:2024.12.09.627542.\|bioRxiv. 2024 Nov 15:2024.11.11.623139.\|Blood Cancer J. 2022 Jan 11;12(1):5.\|Br J Cancer. 2022 Jan 14.\|Breast Cancer Res. 2019 Dec 26;21(1):150.\|Cancer Cell. 2024 Aug 27:S1535-6108(24)00305-2.\|Cancer Discov. 2023 Dec 4.\|Cancer Res. 2017 May 1;77(9):2488-2499.\|Cancer Res. 2019 Oct 15;79(20):5245-5259.\|Cancer Res. 2022 May 16;82(10):1890-1908.\|Cell Chem Biol. 2019 Aug 15;26(8):1067-1080.e8. \|Cell Death Dis. 2020 Oct 28;11(10):925.\|Cell Rep. 2022 Dec 20;41(12):111826.\|Cell Rep. 2024 Dec 30;44(1):115116.\|Cell. 2023 Jun 8;186(12):2628-2643.e21.\|Commun Biol. 2021 Mar 25;4(1):399.\|Department of Biochemistry. 2020 Oct.\|EMBO J. 2024 Aug 19.\|EMBO J. 2024 Oct 24.\|Eur J Drug Metab Pharmacokinet. 2021 Jul 18;1-11.\|Front Oncol. 2021 Jul 13;11:704042.\|Fundam Clin Pharmacol. 2021 Feb 1.\|Heliyon. 2023 Sep 13.\|Int J Biol Sci. 2019 Jan 1;15(3):522-532. \|Int J Mol Sci. 2021 Jan 8;22(2):E575.\|Int J Mol Sci. 2022 Feb 24;23(5):2493.\|J Biol Chem. 2025 Jan 16:108196.\|J Cell Biochem. 2023 Aug 11.\|J Med Chem. 2023 Mar 6.\|J Nanobiotechnology. 2025 Jan 3;23(1):3.\|J Oncol. 2022 Jun 23;2022:8724933.\|J Pharm Anal. 2024 Aug 22.\|JCI Insight. 2021 Dec 21;e154402.\|Leuk Res. September 2022, 106920.\|Mol Cancer Ther. 2024 Jun 19.\|Nat Commun. 2021 Aug 25;12(1):5112.\|Nat Commun. 2021 Nov 16;12(1):6607.\|Nat Commun. 2022 Aug 10;13(1):4689.\|Nat Commun. 2025 Jan 9;16(1):541.\|Nat Metab. 2020 Jan;2(1):41-49.\|Nature Cancer. 2021 Apr;2(4):429-443.\|Naunyn Schmiedebergs Arch Pharmacol. 2023 Feb 4.\|NPJ Precis Oncol. 2021 Mar 19;5(1):20.\|Patent. US20200108066A1\|R Soc Open Sci. 2019 Jan 23;6(1):181714.\|Sci Data. 2024 Sep 19.\|Sci Rep. 2022 Jul 20;12(1):12420.\|Sci Rep. 2024 May 8;14(1):10582.\|Sci Rep. 2019 Oct 22;9(1):15099. \|SSRN. 2022 Nov 21.\|SSRN. 2023 Sep 29.\|Texas Southern University. 2024 July 02.\|Transl Lung Cancer Res. 2024 May 31;13(5):1032-1046.\|Transl Oncol. 2025 Jan 3:52:102264.\|University of Gothenburg. 2023 Jun 27.\|Biochem Biophys Rep. 27, September 2021, 101099\|Biochem Biophys Res Commun. 2018 Sep 26;504(1):231-237. \|Biochem Pharmacol. 2017 Jan 15;124:29-42.\|Biochim Biophys Acta. 2017 Nov 20;1865(2):354-363.\|bioRxiv. 2020 Jun.\|Cancer Res. 2016 Nov 15;76(22):6723-6734. \|Cancer Res. 2023 Jun 29;CAN-23-0705.\|Cell Death Dis. 2019 Mar 20;10(4):271.\|Cell Rep. 2017 Oct 31;21(5):1386-1398.\|Cell Rep. 2022 Sep 13;40(11):111331.\|Cell. 2018 Nov 1;175(4):984-997.e24.\|Clin Cancer Res. 2024 May 8.\|EMBO J. 2022 Jan 5;e108946.\|Harvard Medical School LINCS LIBRARY\|J Exp Clin Cancer Res. 2022 Apr 21;41(1):149.\|J Oncol. 2019 Jun 2;2019:5952836. \|Mol Cell. 2017 Oct 19;68(2):336-349.e6.\|Mol Oncol. 2017 Aug;11(8):1035-1049.\|Nat Commun. 2017 Jun 27;8:15916.\|Nat Commun. 2019 Jun 28;10(1):2860.\|Nature. 2017 Aug 24;548(7668):471-475. \|Nutrition. 2019 Apr;60:217-226. \|Oncotarget. 2017 Jul 27;8(56):95116-95134. \|Oncotarget. 2017 Jun 27;8(40):67422-67438. \|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.\|STAR Protocols. 2020 Jun 3;1(1):100024.
Smiles	CC1=NC2=C(F)C=C(C3=NC(NC4=NC=C(CN5CCN(CC)CC5)C=C4)=NC=C3F)C=C2N1C(C)C
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	LY2835219
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	CDK
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, protect from light)
Molecular Weight	506.59
Product Description	Abemaciclib (LY2835219) is a selective CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively.
Manufacturer - Research Area	Cancer
Solubility	DMSO: 2.94 mg/mL (ultrasonic; warming; heat to 80°C)\|H2O: < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	Cell Cycle/DNA Damage
Isoform	CDK1; CDK2; CDK4; CDK5; CDK6; CDK7; CDK9
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-16297A-1mg-safety-datasheet.pdf